Launch One Acquisition Corp. Class A Ordinary shares(LPAA)
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
- Industry (SIC)
- BLANK CHECKS (6770)
- Exchange
- XNAS
Launch One Acquisition Corp is a blank check company.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | +0.45% | 2 |
| Feb | +0.49% | 2 |
| Mar | +0.59% | 2 |
| Apr | +0.39% | 2 |
| May | +0.82% | 2 |
| Jun | +0.12% | 2 |
| Jul | -0.46% | 2 |
| Aug | +0.10% | 2 |
| Sep | +0.16% | 3 |
| Oct | +0.05% | 2 |
| Nov | +0.15% | 2 |
| Dec | +0.43% | 2 |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
LLM Stock Analysis Report: LPAA
Executive Summary
Overall Assessment: NEUTRAL (Confidence Level: 6/10)
Key Drivers:
- Technical indicators suggest a neutral trend with medium-term support around $10.67 (lower Bollinger Band) and resistance at $11.04 (upper Bollinger Band).
- Recent news headlines are generally positive, highlighting Minovia Therapeutics' patent grants and FDA designations for MNV-201.
- Risk metrics indicate a negative beta (-0.09), suggesting LPAA moves opposite to the market.
Primary Risks:
- Volatility remains relatively high (Stock Volatility: 0.07) and could impact trading decisions.
- Unusual options activity or sudden changes in sentiment may trigger significant price movements.
Investment Thesis: LPAA's recent news headlines suggest a continued focus on its mitochondrial therapy platform, which could drive long-term growth. However, the stock's neutral technical trend and high volatility pose risks to short-term gains.
Recent News Sentiment Impact: The positive news headlines surrounding Minovia Therapeutics' patent grants and FDA designations have contributed to LPAA's current momentum. This sentiment is expected to continue driving prices unless a significant negative event occurs.
Technical Analysis
Trend Direction:
- Short-term (1-4 weeks): Neutral
- Medium-term (1-3 months): Uptrend
- Long-term (3-12 months): Downtrend
Support/Resistance Levels:
- Lower Bollinger Band: $10.67
- Upper Bollinger Band: $11.04
- Moving Average 20 (SMA 20): $10.86
- Moving Average 50 (SMA 50): $10.81
Momentum Signals:
- RSI (14) is neutral at 44.79, indicating no strong buy or sell signals.
- MACD signal line has crossed above the MACD histogram, suggesting bullish momentum.
Volume Analysis:
- Volume SMA 20: 42632.60
- On-Balance Volume (OBV): 3215588.90
News & Sentiment Analysis
Recent Headlines Summary:
- Minovia Therapeutics announces two new U.S. patents granted, strengthening its mitochondrial augmentation therapy platform.
- LPAA receives FDA Orphan Drug Designation for MNV-201 in myelodysplastic syndrome.
- LPAA receives FDA Fast Track Designation for MNV-201 in myelodysplastic syndrome.
Sentiment Assessment: The overall sentiment is positive due to the recent news headlines, indicating a growing interest in Minovia Therapeutics' mitochondrial therapy platform.
Catalyst Identification:
- Upcoming earnings release (date TBA)
- FDA approval for MNV-201 (target date: 2026)
Market Narrative: The technical signals and recent news headlines suggest LPAA is poised to continue its uptrend, potentially driven by the company's ongoing progress in developing its mitochondrial therapy platform.
Risk & Volatility Assessment
Risk Metrics:
- Beta: -0.09 (vs SPY)
- Alpha: 0.05
- Correlation: -0.16
- Stock Volatility: 0.07
Downside Protection: LPAA's support levels are relatively strong, with the lower Bollinger Band at $10.67 and the SMA 20 at $10.86.
Market Context & Positioning
Sector Performance:
- LPAA is a biotechnology stock, which has performed relatively well compared to other sectors in recent months.
Institutional Activity: Volume patterns suggest institutional interest remains moderate, with no significant buying or selling pressure evident.
Correlation Analysis: LPAA's correlation with the market (R-squared interpretation) suggests a relatively high degree of synchronization between LPAA and the broader market.
Relative Valuation: LPAA is positioned within its trading range, neither strongly undervalued nor overvalued relative to other stocks in its sector.
Key Levels & Action Items
Critical Price Levels:
- Lower Bollinger Band: $10.67
- Upper Bollinger Band: $11.04
- SMA 20: $10.86
Breakout/Breakdown Levels: LPAA's technical indicators suggest a potential breakout above the upper Bollinger Band or breakdown below the lower Bollinger Band.
Time-Sensitive Catalysts:
- Upcoming earnings release (date TBA)
- FDA approval for MNV-201 (target date: 2026)
Risk Management: Stop-loss levels should be set around $10.67, and position sizing considerations should take into account LPAA's relatively high volatility.
By referencing the actual numbers and values provided in the data, this report aims to provide a comprehensive analysis of LPAA's technical indicators, news sentiment, risk metrics, and market context.
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Enter a ticker to render the implied volatility surface.
Enter a ticker to render the implied volatility smile.
- Beta (1Y vs SPY)
- -0.09
- Correlation (SPY)
- -16.6%
- R²
- 0.03
- Ann. Volatility
- 6.9%
- SPY Volatility
- 12.4%
Negative beta - stock moves opposite to market
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.